Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology leader developing novel immunotherapies and vaccines for cancer and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on the company’s pioneering work in neoantigen-targeting platforms and self-amplifying mRNA technology.
Access real-time announcements including clinical trial results, regulatory milestones, and strategic collaborations. Our curated collection features:
• Clinical development updates for GRANITE and SLATE vaccine programs
• Technology innovations in AI-driven EDGE platform and samRNA vectors
• Partnership announcements with leading research institutions
• Peer-reviewed data publications and conference presentations
Bookmark this page for streamlined tracking of Gritstone bio’s progress in advancing personalized cancer vaccines and next-generation infectious disease solutions. All content is sourced directly from company filings and verified industry channels.
Gritstone bio (Nasdaq: GRTS) reported financial results for Q4 and full-year 2022, highlighting advancements in its vaccine programs. The company expects preliminary data from its GRANITE Phase 2/3 study for microsatellite-stable colorectal cancer in Q4 2023. Phase 1/2 efficacy signals from the SLATE program are consistent with GRANITE findings. Gritstone ended 2022 with $185.2 million in cash and equivalents, down from $223.5 million in 2021. Research expenses increased to $111.4 million from $97.5 million year-over-year. Collaboration revenues dropped to $19.9 million compared to $48.2 million in 2021. Upcoming milestones include new randomized trials and data releases.
Gritstone bio, Inc. (Nasdaq: GRTS) will release its fourth quarter and full year 2022 financial results on March 9, 2023, after market close. A conference call and audio webcast will follow at 4:30 PM ET. Gritstone is focused on developing potent vaccines targeting viral diseases and solid tumors using innovative vectors to stimulate the immune system. The company aims to advance its product candidates to improve patient outcomes. Investors can access the event online or via phone, with details provided in the press release.
Gritstone bio, a clinical-stage biotechnology firm, announced that its Co-founder and CEO, Andrew Allen, will participate in the "Novel Immuno-Oncology" panel at the Cowen 43rd Annual Healthcare Conference. The event is scheduled for March 6, 2023, from 9:10 to 10:10am ET, at the Boston Marriott Copley Place. A live webcast of the panel will be accessible, with an archived replay available for 30 days.
Gritstone is focused on developing potent vaccines targeting viral diseases and solid tumors, utilizing innovative vectors to enhance immune response. Investors and media inquiries can be directed to their respective contacts provided in the release.
Gritstone bio, Inc. (Nasdaq: GRTS) announced the grant of nonqualified stock options totaling 33,000 shares to three new employees, with an exercise price of $2.71, matching its closing stock price on February 17, 2023. This grant is part of an inducement for the new hires, in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, starting with 25% on the first anniversary of hire, then monthly thereafter, contingent on continued employment. Gritstone bio aims to develop potent vaccines targeting viral diseases and solid tumors.
Gritstone bio has announced a clinical trial agreement with the National Cancer Institute (NCI) to evaluate an autologous T cell therapy in combination with its SLATE-KRAS vaccine for treating mutant KRAS solid tumors. This Phase 1 study will be led by Dr. Steven A. Rosenberg and aims to explore the effectiveness of combining cell therapy and cancer vaccines. With pre-clinical data showing potential efficacy, Gritstone plans to initiate a randomized Phase 2 study in late 2023 based on earlier successes. The study represents a significant collaboration aiming to enhance therapeutic outcomes for patients.
On January 24, 2023, Gritstone bio (Nasdaq: GRTS) announced that its Board of Directors granted nonqualified stock options for 28,000 shares to two new employees. The options come with an exercise price of $3.67, matching the closing price of Gritstone's stock on January 9, 2023. These options are part of an inducement to encourage employment with Gritstone, adhering to Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, contingent on ongoing employment. Gritstone bio specializes in creating potent vaccines targeting viral diseases and solid tumors.
Gritstone bio, a clinical-stage biotechnology firm (Nasdaq: GRTS), announced participation in key investor conferences set for January and February 2023. Andrew Allen, Co-founder and CEO, will lead discussions at the B. Riley Oncology Conference on January 19 and the SVB Securities Global Biopharma Conference on February 16. Celia Economides, CFO, will join a panel at the BIO CEO & Investor Conference on February 6. The events aim to address industry challenges, including CRO spending in a high-inflation environment. Archived replays will be available post-events to provide insights into Gritstone's innovative vaccine development.
Gritstone bio, a clinical-stage biotechnology company, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023. CEO Andrew Allen will speak from 9:45 to 10:25 AM Pacific Time, discussing the company’s efforts to develop potent vaccines targeting critical diseases. A live webcast will be available, and an archived version can be accessed for 30 days after the event. Gritstone is focused on advancing innovative vaccine candidates to improve patient outcomes in viral diseases and solid tumors.
Gritstone bio, Inc. (Nasdaq: GRTS) announced that its Board of Directors has granted nonqualified stock options to five new employees, allowing them to purchase 46,950 shares at an exercise price of $2.69, equivalent to the stock's closing price on December 6, 2022. These options are part of an inducement for employment and will vest over four years, with a fourth of them vesting after one year. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and the company’s 2021 Employment Inducement Incentive Award Plan.
Gritstone bio (Nasdaq: GRTS) announced the issuance of two new patents by the USPTO for its self-amplifying mRNA (samRNA) vaccine platform. U.S. Patent No. 11,504,421 covers personalized cancer vaccine candidates, while No. 11,510,973 pertains to antigen-encoding samRNA vectors, applicable in oncology and infectious diseases. Gritstone's samRNA platform is noted for its extended antigen expression and T cell immunity induction. The company's patent portfolio is expanding, with eight applications granted and around 300 pending.
